---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Incidence"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Incidence. Topics: Estimated U.S. new cases in 2026, all oral cavity and pharynx cancer; Estimated U.S. new cases in 2026 by subsite, all oral cavity, pharynx, and laryngeal cancer; U.S. incidence rate, all oral cavity and pharynx cancer; U.S. incidence rate, all laryngeal cancer; 11 further topics. 15 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/incidence"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of HPV-negative head and neck squamous cell carcinoma

<a id="topic-2.2.1.2.1-1"></a>

### Estimated U.S. new cases in 2026, all oral cavity and pharynx cancer

> “In 2026, an estimated 60,480 new cases of cancer of the oral cavity (mouth) and pharynx (throat) will be diagnosed in the US”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.2.1-2"></a>

### Estimated U.S. new cases in 2026 by subsite, all oral cavity, pharynx, and laryngeal cancer

| Site | Estimated new cases, both sexes | Male | Female |
| --- | --- | --- | --- |
| Oral cavity and pharynx, total | “60,480” | “43,070” | “17,410” |
| Tongue | “20,420” | “14,250” | “6170” |
| Mouth | “15,810” | “9230” | “6580” |
| Pharynx | “21,760” | “17,880” | “3880” |
| Other oral cavity | “2490” | “1710” | “780” |
| Larynx | “12,290” | “9730” | “2560” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.2.1-3"></a>

### U.S. incidence rate, all oral cavity and pharynx cancer

> “The rate of new cases of oral cavity and pharynx cancer was 11.7 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

<a id="topic-2.2.1.2.1-4"></a>

### U.S. incidence rate, all laryngeal cancer

> “The rate of new cases of laryngeal cancer was 2.5 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-2.2.1.2.1-5"></a>

### U.S. incidence trends, all oral cavity and pharynx cancer

> “Incidence rates increased by 0.7% per year during 2013 to 2022, mostly driven by cancers associated with human papillomavirus (HPV) that occur in the oropharynx (the part of the throat behind the oral cavity that includes the back one-third of the tongue, soft palate, and tonsils), which increased by about 2% per year versus a decrease of 1% per year for other oral sites.”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.2.1-6"></a>

### U.S. incidence trend of HPV-negative oropharyngeal cancer

> “Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to 242%) from 1988 to 2004 (from 0.8 per 100,000 to 2.6 per 100,000), and incidence for HPV-negative cancers declined by 50% (95% CI, 47% to 53%; from 2.0 per 100,000 to 1.0 per 100,000).”

Source: [Chaturvedi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3221528/)

<a id="topic-2.2.1.2.1-7"></a>

### HPV-negative share of U.S. oropharyngeal squamous cell carcinoma

| Oropharynx, United States, 2012 to 2016 | Quoted value |
| --- | --- |
| Average annual reported cases | “19,000” |
| Attributable to 9vHPV-targeted types, number (%) | “12,600 (66)” |
| Attributable to other HPV types, number (%) | “900 (5)” |
| HPV-negative, number (%) | “5,500 (29)” |

Source: [Senkomago et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6705893/)

<a id="topic-2.2.1.2.1-8"></a>

### HPV-positive share in a first-line recurrent or metastatic HNSCC trial population

> “Twenty-two percent of patients’ tumors were HPV-positive”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.1.2.1-9"></a>

### HPV status among U.S. real-world first-line pembrolizumab recipients with recurrent or metastatic HNSCC

| HPV status, all subtypes | All patients, n (%) | Pembrolizumab monotherapy, n (%) | Pembrolizumab plus chemotherapy, n (%) |
| --- | --- | --- | --- |
| Positive | “233 (36.1)” | “163 (37.8)” | “70 (32.6)” |
| Negative | “258 (39.9)” | “165 (38.3)” | “93 (43.3)” |
| Equivocal or unknown | “155 (24.0)” | “103 (24.9)” | “52 (24.2)” |

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

<a id="topic-2.2.1.2.1-10"></a>

### Company-stated HPV-negative share of recurrent or metastatic HNSCC

> “Approximately 80% of patients with R/M HNSCC are HPV-negative.”

Source: [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)

<a id="topic-2.2.1.2.1-11"></a>

### Median age at diagnosis by etiology, all HNSCC

> “HNSCC is a cancer of adults, with a median age at diagnosis of 66 years for HPV-negative HNSCC, 53 years for HPV-positive HNSCC and 50 years for EBV-positive HNSCC”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.2.1-12"></a>

### Global new cases in 2024 by subsite, all histologies

| GLOBOCAN 2024 cancer site | New cases | Percentage of all cases |
| --- | --- | --- |
| Lip, oral cavity | “452,205” | “2.2” |
| Larynx | “193,937” | “0.9” |
| Oropharynx | “107,887” | “0.5” |
| Hypopharynx | “91,464” | “0.4” |

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.2.1-13"></a>

### Metastatic disease at diagnosis and recurrence after initial therapy, all HNSCC

> “Ten percent of patients have metastatic disease at diagnosis, and approximately 50% of those with locally advanced HNSCC have recurrence or metastasis after initial therapy.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.1.2.1-14"></a>

### Recurrence after primary treatment of locoregionally advanced HNSCC in U.S. adults aged 66 years or older

> “In the resected cohort, 333 patients (66%) experienced recurrence following their primary treatment, compared with 169 (34%) who remained recurrence-free throughout the follow-up period. In the unresected cohort, 791 patients (65%) developed recurrence and 426 did not (35%)”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-2.2.1.2.1-15"></a>

### Company-stated metastasis and recurrence rates, all HNSCC

> “Ten percent of HNSCC patients are diagnosed with metastatic disease and up to 30% develop a recurrence or metastases over time after receiving initial treatment for advanced HNSCC.”

Source: [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
